These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 37707670)

  • 1. Safety and Efficacy of DT-DEC01 Therapy in Duchenne Muscular Dystrophy Patients: A 12 - Month Follow-Up Study After Systemic Intraosseous Administration.
    Siemionow M; Biegański G; Niezgoda A; Wachowiak J; Czarnota J; Siemionow K; Ziemiecka A; Sikorska MH; Bożyk K; Heydemann A
    Stem Cell Rev Rep; 2023 Nov; 19(8):2724-2740. PubMed ID: 37707670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of Motor Unit Potentials Duration as the Biomarker of DT-DEC01 Cell Therapy Efficacy in Duchenne Muscular Dystrophy Patients up to 12 Months After Systemic-Intraosseous Administration.
    Niezgoda A; Biegański G; Wachowiak J; Czarnota J; Siemionow K; Heydemann A; Ziemiecka A; Sikorska MH; Bożyk K; Siemionow M
    Arch Immunol Ther Exp (Warsz); 2023 Nov; 71(1):24. PubMed ID: 37999748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-up.
    Heydemann A; Bieganski G; Wachowiak J; Czarnota J; Niezgoda A; Siemionow K; Ziemiecka A; Sikorska MH; Bozyk K; Tullius SG; Siemionow M
    Stem Cell Rev Rep; 2023 Jul; 19(5):1340-1359. PubMed ID: 37000376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of Chimeric Cell Therapy in Duchenne Muscular Dystrophy.
    Siemionow M; Ziemiecka A; Bożyk K; Siemionow K
    Biomedicines; 2024 Sep; 12(9):. PubMed ID: 39335509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric Cell Therapy Transfers Healthy Donor Mitochondria in Duchenne Muscular Dystrophy.
    Siemionow M; Bocian K; Bozyk KT; Ziemiecka A; Siemionow K
    Stem Cell Rev Rep; 2024 Oct; 20(7):1819-1829. PubMed ID: 39017908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy.
    Siemionow M; Langa P; Brodowska S; Kozlowska K; Zalants K; Budzynska K; Heydemann A
    Stem Cell Rev Rep; 2022 Dec; 18(8):2872-2892. PubMed ID: 35590083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Biodistribution and Safety of Human Dystrophin Expressing Chimeric Cell Therapy After Systemic-Intraosseous Administration to Duchenne Muscular Dystrophy Model.
    Siemionow M; Brodowska S; Langa P; Zalants K; Kozlowska K; Grau-Kazmierczak W; Heydemann A
    Arch Immunol Ther Exp (Warsz); 2022 Aug; 70(1):20. PubMed ID: 35978142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric Cell Therapies as a Novel Approach for Duchenne Muscular Dystrophy (DMD) and Muscle Regeneration.
    Budzynska K; Siemionow M; Stawarz K; Chambily L; Siemionow K
    Biomolecules; 2024 May; 14(5):. PubMed ID: 38785982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transplantation of Dystrophin Expressing Chimeric Human Cells of Myoblast/Mesenchymal Stem Cell Origin Improves Function in Duchenne Muscular Dystrophy Model.
    Siemionow M; Szilagyi E; Cwykiel J; Domaszewska-Szostek A; Heydemann A; Garcia-Martinez J; Siemionow K
    Stem Cells Dev; 2021 Feb; 30(4):190-202. PubMed ID: 33349121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human dystrophin expressing chimeric (DEC) cell therapy ameliorates cardiac, respiratory, and skeletal muscle's function in Duchenne muscular dystrophy.
    Siemionow M; Langa P; Harasymczuk M; Cwykiel J; Sielewicz M; Smieszek J; Heydemann A
    Stem Cells Transl Med; 2021 Oct; 10(10):1406-1418. PubMed ID: 34291884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dystrophin Expressing Chimeric (DEC) Human Cells Provide a Potential Therapy for Duchenne Muscular Dystrophy.
    Siemionow M; Cwykiel J; Heydemann A; Garcia J; Marchese E; Siemionow K; Szilagyi E
    Stem Cell Rev Rep; 2018 Jun; 14(3):370-384. PubMed ID: 29546607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac Protection after Systemic Transplant of Dystrophin Expressing Chimeric (DEC) Cells to the mdx Mouse Model of Duchenne Muscular Dystrophy.
    Siemionow M; Malik M; Langa P; Cwykiel J; Brodowska S; Heydemann A
    Stem Cell Rev Rep; 2019 Dec; 15(6):827-841. PubMed ID: 31612351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Creation of Dystrophin Expressing Chimeric Cells of Myoblast Origin as a Novel Stem Cell Based Therapy for Duchenne Muscular Dystrophy.
    Siemionow M; Cwykiel J; Heydemann A; Garcia-Martinez J; Siemionow K; Szilagyi E
    Stem Cell Rev Rep; 2018 Apr; 14(2):189-199. PubMed ID: 29305755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amelioration of Morphological Pathology in Cardiac, Respiratory, and Skeletal Muscles Following Intraosseous Administration of Human Dystrophin Expressing Chimeric (DEC) Cells in Duchenne Muscular Dystrophy Model.
    Siemionow M; Budzynska K; Zalants K; Langa P; Brodowska S; Siemionow K; Heydemann A
    Biomedicines; 2024 Mar; 12(3):. PubMed ID: 38540201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial.
    Mendell JR; Sahenk Z; Lehman K; Nease C; Lowes LP; Miller NF; Iammarino MA; Alfano LN; Nicholl A; Al-Zaidy S; Lewis S; Church K; Shell R; Cripe LH; Potter RA; Griffin DA; Pozsgai E; Dugar A; Hogan M; Rodino-Klapac LR
    JAMA Neurol; 2020 Sep; 77(9):1122-1131. PubMed ID: 32539076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigating the role of dystrophin isoform deficiency in motor function in Duchenne muscular dystrophy.
    Chesshyre M; Ridout D; Hashimoto Y; Ookubo Y; Torelli S; Maresh K; Ricotti V; Abbott L; Gupta VA; Main M; Ferrari G; Kowala A; Lin YY; Tedesco FS; Scoto M; Baranello G; Manzur A; Aoki Y; Muntoni F
    J Cachexia Sarcopenia Muscle; 2022 Apr; 13(2):1360-1372. PubMed ID: 35083887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-Transplantation of Bone Marrow-MSCs and Myogenic Stem/Progenitor Cells from Adult Donors Improves Muscle Function of Patients with Duchenne Muscular Dystrophy.
    Klimczak A; Zimna A; Malcher A; Kozlowska U; Futoma K; Czarnota J; Kemnitz P; Bryl A; Kurpisz M
    Cells; 2020 Apr; 9(5):. PubMed ID: 32365922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapy of Duchenne muscular dystrophy with umbilical cord blood stem cell transplantation].
    Zhang C; Feng HY; Huang SL; Fang JP; Xiao LL; Yao XL; Chen C; Ye X; Zeng Y; Lu XL; Wen JM; Zhang WX; Li Z; Feng SW; Xu HG; Huang K; Zhou DH; Chen W; Xie YM; Xi J; Zhang M; Li Y; Liu Y
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2005 Aug; 22(4):399-405. PubMed ID: 16086277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1/2a nonrandomized trial.
    Mendell JR; Sahenk Z; Lehman KJ; Lowes LP; Reash NF; Iammarino MA; Alfano LN; Lewis S; Church K; Shell R; Potter RA; Griffin DA; Hogan M; Wang S; Mason S; Darton E; Rodino-Klapac LR
    Muscle Nerve; 2024 Jan; 69(1):93-98. PubMed ID: 37577753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative electromyography in ambulatory boys with Duchenne muscular dystrophy.
    Verma S; Lin J; Travers C; McCracken C; Shah D
    Muscle Nerve; 2017 Dec; 56(6):1168-1171. PubMed ID: 28457006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.